When administration of the anti-GP1bα antibody was initiated at a later stage (age nine weeks), after the onset of the angiogenic switch, platelet depletion did not suppress tumor growth in HRG-deficient mice (Fig. 6). Here, GP1BA is linked to neoplasm.